Bristol Instruments, Inc., a leader in optical interferometer-based instrumentation, announces an agreement with Qbic Laser System, Inc. Headquartered in Bucheon, South Korea, Qbic will represent Bristol’s laser spectral characterization products, including high-accuracy wavelength meters and high-resolution spectrum analyzers for the characterization of lasers that operate from the visible to the mid-IR.
Bristol Instruments, Inc., a leader in optical interferometer-based instrumentation, announces the addition of Mr. Don Jarvie to its Sales and Marketing Team. Mr. Jarvie will serve as the Business Development Manager for Bristol’s optical metrology products, including its Optical Thickness Gauge for precise non-contact thickness measurement.
Tyndall and Sanmina Corporation have announced a research collaboration, which will focus on the development of a novel wireless technology for a commercial wrist-worn health-monitoring platform.
Bristol Instruments, Inc., the leader in optical interferometer-based instrumentation, has announced the introduction of its QA—“Quick- Align”—optical probe. This new probe, used in combination with Bristol’s 137 and 157 Optical Thickness Gauge products, offers the advantage of a unique alignment aid to ensure the reliable accuracy and exceptional repeatability needed for the most demanding thickness measurement applications.
Adhesives play a critical role in the success of a medical device, whether it’s holding the device together or adhering it to the wearer’s skin. But with so many adhesive products available, it can be a challenge for design engineers to know which one is right for their project. To help bridge this critical gap, 3M developed a “Find My Adhesive” product selector tool to help make medical adhesive selection a simpler process. The product selector tool will be available to demo at CES 2018 in Las Vegas from January 9-12, 2018 in the 3M booth located in Sands, Halls A-D; 43517 Health & Wellness Marketplace.
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced it has received U.S. Food and Drug Administration (FDA) clearance for the Sidus® Stem-Free Shoulder system as a total shoulder arthroplasty solution for patients with good bone stock that have either osteoarthritis, post-traumatic arthrosis, focal avascular necrosis of the humeral head or who had previous surgeries of the shoulder that do not compromise the fixation.
When studying diseases or testing potential drug therapies, researchers usually turn to cultured cells on Petri dishes or experiments with lab animals, but recently, researchers have been developing a different approach: small, organ-on-a-chip devices that mimic the functions of human organs, serving as potentially cheaper and more effective tools.
Cells communicate with each other through a number of different mechanisms. Some of these mechanisms are well-known: in animals, for example, predatory threats can drive the release of norepinephrine, a hormone that travels through the bloodstream and triggers heart and muscle cells to initiate a "fight-or-flight" response.
K2M Group Holdings, Inc.(NASDAQ:KTWO) (the "Company" or "K2M"), a global leader of complex spine and minimally invasive solutions focused on achieving three-dimensional Total Body Balance™, today announced that it received a CE Mark for its CAPRI® Cervical 3D Expandable Corpectomy Cage System* featuring Lamellar 3D Titanium Technology™, and the successful completion of its first surgical case.
Each year 40,000 babies in the U.S. are born with a congenital heart defect, often caused by a defective heart valve, which is estimated to account for 8,000 to 13,000 new cases in the U.S. alone.
|
|
|
|
|
|
|
|
|